Business
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual
About this update from Alkermes Plc
[{"type":"text","content":"\nAlkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company’s psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes’ proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 receptor agonists, including alixorexton, ALKS 4510 and ALKS 7290.\n\n\n“Alkermes brings decades of experience advancing innovative medicines in neuroscience and psychiatry, underpinned by deep scientific expertise. Our poster presentations at ASCP reflect our continued commitment to advancing both the understanding of, and treatment options for, complex psychiatric and neurological conditions. In particular, we are proud to share new research from our orexin portfolio as we work to deepen our understanding of orexin biology across a range of neuropsychiatric indications,” said Craig Hopkinson, M.D. (MBChB), Chief Medical Officer and Executive Vice President, Research & Development at Alkermes.\n\n\nHighlights of the ASCP poster presentations include:\n\n\n\nFindings from the ASPIRE survey study evaluating the impact of cognitive impairment and fatigue on work productivity and health-related quality of life in people with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.\n\n\n\nFirst presentation of data supporting the rationale for our orexin 2 receptor agonist portfolio as potential therapeutic treatments of sleep-wake disturbance, fatigue and cognitive deficit in neuropsychiatric diseases.\n\n\n\nReal-world, retrospective claims analysis evaluating persistence and adherence on LYBALVI compared to other oral second-generation antipsychotic medications among adults with schizophrenia.\n\n\nA full list of Alkermes’ poster presentations at ASCP follows:\n\n\nWednesday, May 27, 2026, 11:45 am – 1:30 pm ET\n\nPoster #W52: “Orexin 2 Receptor Agonists as a Potential Therapeutic Approach to the Treatment of Sleep-Wake Disturbance, Fatigue, and Cognitive Deficit in Neuropsychiatric Disease,” will be presented by David Plante, M.D., Ph.D., University of Wisconsin-Madison\n\n\n\nPoster #W79: “Real-World Experience and Impact of Fatigue in Narcolepsy and...